Cholangiocarcinoma: what are the most valuable therapeutic targets – cancer-associated fibroblasts, immune cells, or beyond T cells?. (3rd October 2021)

• Record Type: Journal Article
• Authors: Wang, Juan; Loeuillard, Emilien; Gores, Gregory J.; Ilyas, Sumera I.
• Is Part Of: Expert opinion on therapeutic targets. Volume 25:Number 10(2021)
• Page Start: 835
• Page End: 845
• Publication Date: 2021-10-03
• Subjects: Cholangiocarcinoma -- biliary tract -- immune cells -- tumor immunology -- cancer associated fibroblast -- myeloid cells -- immune checkpoint inhibition; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2021.2010046
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: CCAs are dense and desmoplastic tumors with an abundant tumor microenviroment (TME). The evolving TME is characterized by reciprocal interactions between cancer cells and their environment and is essential in facilitating tumor progression. The TME has nonimmune and immune components. Nonimmune cell types include cancer-associated fibroblasts (CAFs) and endothelial cells accompanying tumor angiogenesis. Immune cell types include elements of the innate and adaptive immune response, and can have pro-tumor or antitumor roles. The TME can shape treatment response and resistance. Therefore, elements of the TME are attractive therapeutic targets. TME targeting therapies have been evaluated in preclinical and clinical studies but only a small subset of patients has a meaningful response. Areas covered: We discuss the TME components and potential TME targeting strategies. Literature search was performed on PubMed and ClinicalTrials.gov until October 2021. Expert opinion: Elucidating the CCA TME is essential for developing effective treatment strategies. Preclinical models that recapitulate the disease (such as organoids) are important tools in uncovering the intricate cross talk in the CCA TME. Characterization of patient-derived specimens using multi-omic and single-omic technologies can dissect the cellular interplay in the CCA TME, which can guide development of effective treatment strategies and identify biomarkers for patient stratification.